Martinsried/Munich, 18 May, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming investment and scientific conferences:
• BioEquity Europe - The 16th Collaborative Gathering of Corporate & Investment Communities for the European Life Science
Date: 19 - 20 May 2015
Location: Vienna, Austria
Company presentation: 19 May 4.40 pm local time Speaker: Peter Llewellyn-Davies, CFO Medigene AG .
• Conférence du LICR, Ludwig Center for Cancer Research of the University of Lausanne
Date: 21 May 2015
Location: Lausanne, Switzerland
Speaker: Dolores J. Schendel, CSO Medigene AG
• ASCO, American Society of Clinical Oncology Annual Meeting 2015
Date: 29 May - 02 June 2015
Location: Chicago, USA
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Help employers find you! Check out all the jobs and post your resume.
